Importantly, the combination of FAP-targeted immunostimulatory drugs with glofitamab increased anti-DLBCL TIL killing function when TILs were interacting with FAP+ DLBCL-FRCs(c), but not FRCs lacking detectable FAP expression (Supplemental Figure 10D). The gene discussed is FAP; the disease is diffuse large B-cell lymphoma.